Statin–Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial
Circulation · 2026-11-07
DOI: 10.1161/circulationaha.126.083811 ↗Abstract
BACKGROUND: In a target-directed low-density lipoprotein cholesterol (LDL-C)–lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease. We compared the efficacy and safety of initial statin–ezetimibe combination therapy versus statin monotherapy within intensive or conventional LDL-C–targeting strategies. METHODS: In this prespecified second randomization of the randomized Ez-PAVE trial (Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease: Randomized Comparison of LDL Cholesterol Targeting
EUVIMED